This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by King, I. B. Articles by Goodman, G. E. Search for Related Content PubMed PubMed Citation Articles by King, I. B. Articles by Goodman, G. E.

Serum Trans-Fatty Acids Are Associated with Risk of Prostate Cancer in ß-Carotene and Retinol Efficacy Trial

¹ Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, ² School of Public Health and Community Medicine, ³ Environmental Health, University of Washington; and ⁴ Swedish Medical Center Tumor Institute, Seattle, Washington

Requests for reprints: Irena B. King, Public Health Sciences Laboratories, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Suite M-5A864, Seattle WA 98109-1024. E-mail: iking{at}fhcrc.org

Biomarkers of trans-fatty acid consumption have been associated with increased risks of breast and colon cancer, although no studies have examined their associations with prostate cancer risk. Using data from the ß-Carotene and Retinol Efficacy Trial, this nested case-control study examined the relationships between serum phospholipid trans-fatty acids and prostate cancer incidence in 272 case and 426 control men. Trans-fatty acids were measured using organic extraction followed by separations with TLC and gas chromatography. Adjusted odds ratios for risk of prostate cancer with increasing levels of trans-fatty acids were calculated using logistic regression. There were consistent trends for increasing prostate cancer risk with higher levels of C18 but not C16 trans-fatty acids, although only trends for 11t 18:1 trans-vaccenic and 9c,12t 18:2 fatty acids reached statistical significance. Odds ratios (95% confidence interval) contrasting low versus high quartiles for these fatty acids were 1.69 (1.03-2.77) and 1.79 (1.02-3.15), respectively. There were no consistent differences in associations between low-grade and high-grade cancer among the subset of 209 cases with information on tumor grade. Additional studies are needed to confirm these findings and better control for factors, such as use of prostate-specific antigen screening, which may confound this association.

This article has been cited by other articles:

				J. E. Chavarro, M. J. Stampfer, H. Campos, T. Kurth, W. C. Willett, and J. Ma A Prospective Study of Trans-Fatty Acid Levels in Blood and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 95 - 101. [Abstract] [Full Text] [PDF]

				J.-Y. Choi, M. L. Neuhouser, M. Barnett, M. Hudson, A. R. Kristal, M. Thornquist, I. B. King, G. E. Goodman, and C. B. Ambrosone Polymorphisms in Oxidative Stress-Related Genes Are Not Associated with Prostate Cancer Risk in Heavy Smokers Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1115 - 1120. [Abstract] [Full Text] [PDF]

				X. Liu, F. R. Schumacher, S. J. Plummer, E. Jorgenson, G. Casey, and J. S. Witte trans-Fatty acid intake and increased risk of advanced prostate cancer: modification by RNASEL R462Q variant Carcinogenesis, June 1, 2007; 28(6): 1232 - 1236. [Abstract] [Full Text] [PDF]

				K. Kuhnt, A. Wagner, J. Kraft, S. Basu, and G. Jahreis Dietary supplementation with 11trans- and 12trans-18:1 and oxidative stress in humans. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 981 - 988. [Abstract] [Full Text] [PDF]